Dr Gerard van Odijk


Drs. Gerard WM van Odijk has an over 25 years track record in the health care industry. From 2006 until the middle of 2012 he has served as President and CEO of Teva Pharmaceuticals Europe. In which role he has been deeply involved in the many successful acquisitions of Teva. He obtained his medical degree from Utrecht University. Following his academic degree, he has held various international executive position and a senior position in GlaxoSmithKline (GSK). Since 2013 he is an independent healthcare industrial advisor. Gerard currently serves as Chairman of the Board for Bavarian Nordic A/S.  He also is Chairman of the Board of Curaeos bv and until recently  Chairman of HTL-Strefa S.A. Before this Gerard has been chairman of Merus n.v. and Syntarga bv. He also served as Non-Executive Board member on the Board of UDG Healthcare plc, Neurogen A/S  and Alvogen Sárl. He is member of the advisory board of the Dutch Medicine Agency.

April 10, 2019 HUB and Yamaha Motor Announce their Collabora... February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their co... read more
April 09, 2019 Hubrecht Organoid Technology and Crownbio ann... March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscien... read more